Reasons to get blood tested – What for? When?
What labs to get?
Fasting or not?
Where to get your blood test order (requisition)?
1. Bhasin, S., et al., Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab, 2011. 96(8): p. 2430-9.
2. Haring, R., et al., Age-specific reference ranges for serum testosterone and androstenedione concentrations in women measured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab, 2012. 97(2): p. 408-15.
3. Crabbe, P., et al., Part of the interindividual variation in serum testosterone levels in healthy men reflects differences in androgen sensitivity and feedback set point: contribution of the androgen receptor polyglutamine tract polymorphism. J Clin Endocrinol Metab, 2007. 92(9): p. 3604-10.
4. Francomano, D., et al., CAG repeat testing of androgen receptor polymorphism: is this necessary for the best clinical management of hypogonadism? J Sex Med, 2013. 10(10): p. 2373-81.
5. Liu, C.C., et al., The impact of androgen receptor CAG repeat polymorphism on andropausal symptoms in different serum testosterone levels. J Sex Med, 2012. 9(9): p. 2429-37.
6. Zitzmann, M., The role of the CAG repeat androgen receptor polymorphism in andrology. Front Horm Res, 2009. 37: p. 52-61.
7. Garmendia Madariaga, A., et al., The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J Clin Endocrinol Metab, 2014. 99(3): p. 923-31.
8. Hollowell, J.G., et al., Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab, 2002. 87(2): p. 489-99.
9. Shapira, N., Women’s higher health risks in the obesogenic environment: a gender nutrition approach to metabolic dimorphism with predictive, preventive, and personalised medicine. EPMA J, 2013. 4(1): p. 1.
10. Knudsen, N., et al., Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. J Clin Endocrinol Metab, 2005. 90(7): p. 4019-24.
11. Fox, C.S., et al., Relations of thyroid function to body weight: cross-sectional and longitudinal observations in a community-based sample. Arch Intern Med, 2008. 168(6): p. 587-92.
12. Bjergved, L., et al., Thyroid function and body weight: a community-based longitudinal study. PLoS One, 2014. 9(4): p. e93515.
13. Laurberg, P., et al., Thyroid function and obesity. Eur Thyroid J, 2012. 1(3): p. 159-67.
14. Cooper, D.S. and B. Biondi, Subclinical thyroid disease. Lancet, 2012. 379(9821): p. 1142-54.
15. Khandelwal, D. and N. Tandon, Overt and subclinical hypothyroidism: who to treat and how. Drugs, 2012. 72(1): p. 17-33.
16. Davison, S.L. and S.R. Davis, Androgenic hormones and aging–the link with female sexual function.Horm Behav, 2011. 59(5): p. 745-53.
17. Davis, S.R., Androgen therapy in women, beyond libido. Climacteric, 2013. 16 Suppl 1: p. 18-24.
18. Medline Plus. Comprehensive metabolic panel. Available at https://www.nlm.nih.gov/medlineplus/ency/article/003468.htm (accessed July, 2016).
19. Lab Tests Online. Comprehensive metabolic panel (CMP). Available at https://labtestsonline.org/understanding/analytes/cmp/tab/sample/ (accessed July, 2016).
20. Nordestgaard, B.G., et al., Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J, 2016.
21. Blaak, E.E., et al., Impact of postprandial glycaemia on health and prevention of disease. Obes Rev, 2012. 13(10): p. 923-84.
22. Lind, M., et al., The association between HbA1c, fasting glucose, 1-hour glucose and 2-hour glucose during an oral glucose tolerance test and cardiovascular disease in individuals with elevated risk for diabetes. PLoS One, 2014. 9(10): p. e109506.
23. Peter, R., et al., Postprandial glucose – a potential therapeutic target to reduce cardiovascular mortality. Curr Vasc Pharmacol, 2009. 7(1): p. 68-74.